Search

Your search keyword '"Reinisch, M."' showing total 185 results
Start Over Author "Reinisch, M."
185 results on '"Reinisch, M."'

1. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

Author

Meyer-Wilmes, P., Huober, J., Untch, M., Blohmer, J.-U., Janni, W., Denkert, C., Klare, P., Link, T., Rhiem, K., Bayer, C., Reinisch, M., Bjelic-Radisic, V., Zahm, D.M., Hanusch, C., Solbach, C., Heinrich, G., Hartkopf, A.D., Schneeweiss, A., Fasching, P., Filmann, N., Nekljudova, V., Holtschmidt, J., Stickeler, E., and Loibl, S.

Published
2024
Full Text
View/download PDF

2. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Author

Kieback, Dirk Günter, van Mackelenbergh, Marion Tina, Hielscher, Carsten, Ugur, Mustafa Celalettin, Uleer, Christoph, Zahn, Mark-Oliver, Meyer, Ralf, Kraudelt, Susanne, Stefek, Andrea, Pink, Daniel, Just, Marianne, Kolberg, Hans-Christian, Fehm, Tanja, Malter, Wolfram, Warm, Mathias, Forstbauer, Helmut, Behringer, Dirk, Wortmann, Anke, Rom, Joachim, Lehnert, Antje, Ackermann, Sven, Guth, Dagmar, Simon, Eike, Dünnebacke, Jan, Hönig, Arnd, Ehscheidt, Peter, Gnauert, Karsten, Kühn, Thorsten, von Abel, Ekkehard, Hartkopf, Andreas, Karck, Ulrich, Negwer, Martina, Wacker, Jürgen, Welslau, Manfred, Sagasser, Jaqueline, Heinrichm, Bernhard, Brucker, Cosima, Stauder, Heribert, Gröll, Isolde, Felberbaum, Ricardo, Popovic, Milos, Baerens, Dirk-Toralf, Söling, Ulrike, Zaiss, Matthias, Rauh, Jaqueline, Fietz, Thomas, Schröder, Jan, Voß, Hermann, Mohm, Johannes, Neef, Ute, Rieger, Lorenz, Distelrath, Andrea, Nusch, Arnd, Schmidt, Burkhard, Lüdtke-Heckenkamp, Kerstin, Berghorn, Michael, Busch, Steffi, Schock, Caroline, Metz, Michael, Lorenz, Andreas, Uhlig, Jens, Otremba, Burkhard, Harbeck, N., Fasching, P.A., Wuerstlein, R., Degenhardt, T., Lüftner, D., Kates, R.E., Schumacher, J., Räth, P., Hoffmann, O., Lorenz, R., Decker, T., Reinisch, M., Göhler, T., Staib, P., Gluz, O., Schinköthe, T., and Schmidt, M.

Published
2023
Full Text
View/download PDF

3. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

Author

Schmidt, M., Lübbe, K., Decker, T., Thill, M., Bauer, L., Müller, V., Link, T., Furlanetto, J., Reinisch, M., Mundhenke, C., Hoffmann, O., Zahn, M.-O., Müller, L., Denkert, C., van Mackelenbergh, M., Fasching, P.A., Burchardi, N., Nekljudova, V., and Loibl, S.

Published
2022
Full Text
View/download PDF

5. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Author

Zhang, Q., Xu, B., Shao, Z., Wang, X., Geng, C., Yan, X., Tong, Z., Shen, K., Yin, Y., Sun, T., Yang, J., Feng, J., Yan, M., Wang, Y., Liu, Q., Zhang, S., De Laurentiis, M., Santoro, A., Guarneri, V., Colleoni, M., Natoli, C., Cortesi, L., Placido, S., Gianni, L., Ferrau, F., Livi, L., Zambelli, A., Del Mastro, L., Tonini, G., Montemurro, F., Bianchi, G., Pedersini, R., Prete, S., Allegrini, G., Naso, G., Vici, P., Loirat, D., Mailliez, A., Priou, F., Tredan, O., Dalenc, F., Perrin, C., Gligorov, J., Timar David, M., Dohollou, N., Teixeira, L., Brocard, F., Arnaud, A., Delaloge, S., Spano, J.-P., Mansi, L., Andrade, L., Damian, F., Pedrini, J., Aleixo, S., Hegg, R., Junior, R., Reinisch, M., Schmidt, M., Wenzel, C., Grischke, E.-M., Schneeweiss, A., Just, M., Harbeck, N., Schumacher, C., Peters, U., Fischer, D., Forstbauer, H., Liersch, R., Warner, E., Bouganim, N., Doyle, C., Price Hiller, J., Vandenberg, T., Pavic, M., Robinson, A., Roldan Urgoiti, G., Califaretti, N., Alacacioglu, A., Gumus, M., Yalcin, B., Cicin, I., Kose, F., Uygun, K., Kaplan, M., Cubukcu, E., Wardley, A., Harries, M., Miles, D., Doval, D., Gupta, S., Mohapatra, P., Chatterjee, S., Ghadyalpatil, N., Singhal, M., Nag, S., Agarwal, A., Wolf, I., Gal Yam, E., Yerushalmi, R., Peretz, T., Fried, G., Ben Baruch, N., Katz, D., Hamilton, E., Kayali, F., Brufsky, A., Telli, M., Wright, G., Oyola, R., Rakowski, T., Graff, S., Tjulandin, S., Semiglazov, V., Aparicio, A., Ruiz Borrego, M., Merino, L., Guerra Martinez, J., Lopez, E., Yamashita, T., Ohtani, S., Inoue, K., Ito, Y., Niikura, N., Nakayama, T., Sagara, Y., Yanagita, Y., Kamada, Y., Kaneko, K., Kaen, D., Nervo, A., Eniu, A., Schenker, M., Priester, P., Melichar, B., Zimovjanova, M., Sormova, P., Sufliarsky, J., Kakalejcik, M., Belbaraka, R., Errihani, H., Le Than, D., Pham, D., Aravantinos, G., Papadimitriou, C., Koumakis, G., Papandreou, C., Podolski, P., Tabane, K., André, F., Cameron, D., Barrios, C., Patel, S., Patre, M., Morales, L., Patel, S.L., Kaul, M., Barata, T., and O’Shaughnessy, J.

Published
2021
Full Text
View/download PDF

6. Standards in der adjuvanten Systemtherapie des Mammakarzinoms

Author

Reinisch, M., Kümmel, S., Adamietz, Irenäus A., editor, Bechstein, Wolf O., editor, Christiansen, Hans, editor, Doehn, Christian, editor, Hochhaus, Andreas, editor, Hofheinz, Ralf-Dieter, editor, Lichtenegger, Werner, editor, Lordick, Florian, editor, Schadendorf, Dirk, editor, Untch, Michael, editor, and Wittekind, Christian, editor

Published
2016
Full Text
View/download PDF

7. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: Primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Author

Harbeck, N., primary, Fasching, P.A., additional, Würstlein, R., additional, Degenhardt, T., additional, Lüftner, D., additional, Kates, R.E., additional, Schumacher, J., additional, Räth, P., additional, Hoffmann, O., additional, Lorenz, R., additional, Decker, T., additional, Reinisch, M., additional, Göhler, T., additional, Staib, P., additional, Gluz, O., additional, Schinköthe, T., additional, and Schmidt, M., additional

Published
2023
Full Text
View/download PDF

8. 195P Impact of an interactive eHealth system for patient reported outcomes on safety in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy

Author

Harbeck, N., primary, Kates, R.E., additional, Schinköthe, T., additional, Schumacher, J., additional, Degenhardt, T., additional, Würstlein, R., additional, Lüftner, D.I., additional, Hoffmann, O., additional, Raeth, P., additional, Lorenz, R., additional, Decker, T., additional, Reinisch, M., additional, Göhler, T., additional, Staib, P., additional, Gluz, O., additional, Fasching, P.A., additional, and Schmidt, M., additional

Published
2023
Full Text
View/download PDF

9. 200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa

Author

Loibl, S., primary, Reinisch, M., additional, Denkert, C., additional, Fasching, P.A., additional, Seiler, S., additional, Link, T., additional, Hanusch, C., additional, Bjelic-Radisic, V., additional, Schneeweiss, A., additional, Huober, J., additional, Jackisch, C., additional, Rhiem, K.E., additional, Untch, M., additional, Solbach, C., additional, Blohmer, J-U., additional, Buechele, T., additional, Nekljudova, V., additional, and Loi, S., additional

Published
2022
Full Text
View/download PDF

11. Intelligente vakuum-assistierte Biopsie zur Identifikation von Brustkrebspatientinnen mit pathologischer Komplettremmission (ypT0, ypN0) nach neoadjuvanter Systemtherapie für den Verzicht einer Operation von Brust und Axilla

Author

Pfob, A., additional, Sidey-Gibbons, C., additional, Rauch, G., additional, Thomas, B., additional, Schäfgen, B., additional, Kuemmel, S., additional, Reimer, T., additional, Hahn, M., additional, Thill, M., additional, Blohmer, J.-U., additional, Hackmann, J., additional, Malter, W., additional, Bekes, I., additional, Friedrichs, K., additional, Wojcinski, S., additional, Joos, S., additional, Paepke, S., additional, Degenhardt, T., additional, Rom, J., additional, Rody, A., additional, van Mackelenbergh, M., additional, Banys-Paluchowski, M., additional, Große, R., additional, Reinisch, M., additional, Karsten, M., additional, Golatta, M., additional, and Heil, J., additional

Published
2022
Full Text
View/download PDF

13. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

Author

Rugo, H S, O'Shaughnessy, J, Boyle, F, Toi, M, Broom, R, Blancas, I, Gumus, M, Yamashita, T, Im, Y-H, Rastogi, P, Zagouri, F, Song, C, Campone, M, San Antonio, B, Shahir, A, Hulstijn, M, Brown, J, Zimmermann, A, Wei, R, Johnston, S R D, Reinisch, M, Tolaney, S M, and monarchE Committee Members

Subjects
safety, Diarrhea, Receptor, ErbB-2, HER2 negative, Aminopyridines, HR positive, Breast Neoplasms, Hematology, abemaciclib, monarchE, Oncology, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Benzimidazoles, Female, Patient Reported Outcome Measures, early breast cancer, Neoplasm Recurrence, Local
Abstract

In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at a median follow-up of 27 months and key patient-reported outcomes (PROs) are presented. The safety population included all patients who received at least one dose of study treatment (n = 5591). Safety analyses included incidence, management, and outcomes of common and clinically relevant adverse events (AEs). Patient-reported health-related quality of life, ET symptoms, fatigue, and side-effect burden were assessed. The addition of abemaciclib to ET resulted in higher incidence of grade ≥3 AEs (49.7% versus 16.3% with ET alone), predominantly laboratory cytopenias [e.g. neutropenia (19.6%)] without clinical complications. Abemaciclib-treated patients experienced more serious AEs (15.2% versus 8.8%). Discontinuation of abemaciclib and/or ET due to AEs occurred in 18.5% of patients, mainly due to grade 1/2 AEs (66.8%). AEs were managed with comedications (e.g. antidiarrheals), abemaciclib dose holds (61.7%), and/or dose reductions (43.4%). Diarrhea was generally low grade (grade 1/2: 76%); grade 2/3 events were highest in the first month (20.5%), most were short-lived (≤7 days) and did not recur. Venous thromboembolic events (VTEs) were higher with abemaciclib + ET (2.5%) versus ET (0.6%); in the abemaciclib arm, increased VTE risk was observed with tamoxifen versus aromatase inhibitors (4.3% versus 1.8%). PROs were similar between arms, including being 'bothered by side-effects of treatment', except for diarrhea. At ≥3 months, most patients reporting diarrhea reported 'a little bit' or 'somewhat'. In patients with high-risk EBC, adjuvant abemaciclib + ET has an acceptable safety profile and tolerability is supported by PRO findings. Most AEs were reversible and manageable with comedications and/or dose modifications, consistent with the known abemaciclib toxicity profile.

Published
2022

14. A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)-GeparPiPPa

Author

Loibl, S., Reinisch, M., Denkert, C., Fasching, P. A., Seiler, S., Link, T., Hanusch, C., Bjelic-Radisic, V., Schneeweiss, A., Huober, J., Jackisch, C., Rhiem, K. E., Untch, M., Solbach, C., Blohmer, J-U., Buechele, T., Nekljudova, V., Loi, S., Loibl, S., Reinisch, M., Denkert, C., Fasching, P. A., Seiler, S., Link, T., Hanusch, C., Bjelic-Radisic, V., Schneeweiss, A., Huober, J., Jackisch, C., Rhiem, K. E., Untch, M., Solbach, C., Blohmer, J-U., Buechele, T., Nekljudova, V., and Loi, S.

Published
2022

15. Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)

Author

Reinisch, M., Blohmer, J-U., Link, T., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Thill, M., Jackisch, C., Rhiem, K., Solbach, C., Hanusch, C., Denkert, C., Engels, K., Nekljudova, V., Loibl, S., Reinisch, M., Blohmer, J-U., Link, T., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Thill, M., Jackisch, C., Rhiem, K., Solbach, C., Hanusch, C., Denkert, C., Engels, K., Nekljudova, V., and Loibl, S.

Published
2022

17. 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

Author

Marmé, F., primary, Hanusch, C., additional, Furlanetto, J., additional, Morris, P., additional, Link, T., additional, Denkert, C., additional, Fasching, P.A., additional, Jackisch, C., additional, Antolín, S., additional, Solbach, C., additional, Aftimos, P., additional, Huober, J., additional, Untch, M., additional, Balic, M., additional, Reinisch, M., additional, Blohmer, J-U., additional, Gonçalves, A., additional, Rey, J., additional, Büchele, T., additional, and Loibl, S., additional

Published
2022
Full Text
View/download PDF

18. 92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) primary breast cancer (BC): CheckMate 7A8

Author

Jerusalem, G., primary, Prat, A., additional, Salgado, R.F., additional, Reinisch, M., additional, Saura, C., additional, Ruiz Borrego, M., additional, Nikolinakos, P., additional, Filian, J., additional, Ades, F., additional, Huang, N., additional, Mazzei-Abba, A., additional, and Tolaney, S.M., additional

Published
2022
Full Text
View/download PDF

19. 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)

Author

Reinisch, M., primary, Blohmer, J-U., additional, Link, T., additional, Just, M., additional, Untch, M., additional, Stötzer, O., additional, Fasching, P.A., additional, Schneeweiss, A., additional, Wimberger, P., additional, Seiler, S., additional, Huober, J., additional, Thill, M., additional, Jackisch, C., additional, Rhiem, K., additional, Solbach, C., additional, Hanusch, C., additional, Denkert, C., additional, Engels, K., additional, Nekljudova, V., additional, and Loibl, S., additional

Published
2022
Full Text
View/download PDF

21. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

Author

Rugo, H.S. O'Shaughnessy, J. Boyle, F. Toi, M. Broom, R. Blancas, I. Gumus, M. Yamashita, T. Im, Y.-H. Rastogi, P. Zagouri, F. Song, C. Campone, M. San Antonio, B. Shahir, A. Hulstijn, M. Brown, J. Zimmermann, A. Wei, R. Johnston, S.R.D. Reinisch, M. Tolaney, S.M. monarchE Committee Members

Abstract

BACKGROUND: In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at a median follow-up of 27 months and key patient-reported outcomes (PROs) are presented. PATIENTS AND METHODS: The safety population included all patients who received at least one dose of study treatment (n = 5591). Safety analyses included incidence, management, and outcomes of common and clinically relevant adverse events (AEs). Patient-reported health-related quality of life, ET symptoms, fatigue, and side-effect burden were assessed. RESULTS: The addition of abemaciclib to ET resulted in higher incidence of grade ≥3 AEs (49.7% versus 16.3% with ET alone), predominantly laboratory cytopenias [e.g. neutropenia (19.6%)] without clinical complications. Abemaciclib-treated patients experienced more serious AEs (15.2% versus 8.8%). Discontinuation of abemaciclib and/or ET due to AEs occurred in 18.5% of patients, mainly due to grade 1/2 AEs (66.8%). AEs were managed with comedications (e.g. antidiarrheals), abemaciclib dose holds (61.7%), and/or dose reductions (43.4%). Diarrhea was generally low grade (grade 1/2: 76%); grade 2/3 events were highest in the first month (20.5%), most were short-lived (≤7 days) and did not recur. Venous thromboembolic events (VTEs) were higher with abemaciclib + ET (2.5%) versus ET (0.6%); in the abemaciclib arm, increased VTE risk was observed with tamoxifen versus aromatase inhibitors (4.3% versus 1.8%). PROs were similar between arms, including being 'bothered by side-effects of treatment', except for diarrhea. At ≥3 months, most patients reporting diarrhea reported 'a little bit' or 'somewhat'. CONCLUSIONS: In patients with high-risk EBC, adjuvant abemaciclib + ET has an acceptable safety profile and tolerability is supported by PRO findings. Most AEs were reversible and manageable with comedications and/or dose modifications, consistent with the known abemaciclib toxicity profile. Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Published
2022

23. PREcoopERA Window-of-Opportunity trial of giredestrant+/- triptorelin vs. anastrozole+triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

Author

Bjelic-Radisic, V., Munzone, E., Untch, M., Denkert, C., Hirmas, N., Reinisch, M., Solbach, C., Marmé, F., Link, T., van Mackelenbergh, M., Rhiem, K., Langanke, D., Blohmer, J.-U., Reimer, T., Huober, J., Rack, B., Oskay-Öczelik, G., Regan, M., Dubsky, P., and Loibl, S.

Published
2024
Full Text
View/download PDF

24. 199TiP Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA

Author

Marmé, F., primary, Hanusch, C., additional, Furlanetto, J., additional, Denkert, C., additional, Link, T., additional, Untch, M., additional, Blohmer, J-U., additional, Jackisch, C., additional, Reinisch, M., additional, Rhiem, K.E., additional, Schneeweiss, A., additional, Solbach, C., additional, Schöllhorn, L., additional, Fasching, P.A., additional, Rey, J., additional, and Loibl, S., additional

Published
2021
Full Text
View/download PDF

25. 201TiP Evaluation of the feasibility of ultrasound-guided clipping of suspicious intramammary lesions in primary breast cancer patients receiving neoadjuvant therapy (Ultra3Detect)

Author

Vlachou, E., primary, Kümmel, S., additional, Künzel, N., additional, Breit, E., additional, Schindowski, D., additional, Pankert, K., additional, Hentsch, S., additional, Hanf, V., additional, Weber, D., additional, Graßhoff, S-T., additional, Müller, C., additional, Lucke, W., additional, Deuschle, P., additional, Engellandt, K., additional, Rüland, A., additional, Dall, P., additional, Harrach, H., additional, Bruzas, S., additional, Chiari, O., additional, and Reinisch, M., additional

Published
2021
Full Text
View/download PDF

26. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Author

Miles, D., primary, Gligorov, J., additional, André, F., additional, Cameron, D., additional, Schneeweiss, A., additional, Barrios, C., additional, Xu, B., additional, Wardley, A., additional, Kaen, D., additional, Andrade, L., additional, Semiglazov, V., additional, Reinisch, M., additional, Patel, S., additional, Patre, M., additional, Morales, L., additional, Patel, S.L., additional, Kaul, M., additional, Barata, T., additional, O’Shaughnessy, J., additional, Zhang, Q., additional, Shao, Z., additional, Wang, X., additional, Geng, C., additional, Yan, X., additional, Tong, Z., additional, Shen, K., additional, Yin, Y., additional, Sun, T., additional, Yang, J., additional, Feng, J., additional, Yan, M., additional, Wang, Y., additional, Liu, Q., additional, Zhang, S., additional, De Laurentiis, M., additional, Santoro, A., additional, Guarneri, V., additional, Colleoni, M., additional, Natoli, C., additional, Cortesi, L., additional, Placido, S., additional, Gianni, L., additional, Ferrau, F., additional, Livi, L., additional, Zambelli, A., additional, Del Mastro, L., additional, Tonini, G., additional, Montemurro, F., additional, Bianchi, G., additional, Pedersini, R., additional, Prete, S., additional, Allegrini, G., additional, Naso, G., additional, Vici, P., additional, Loirat, D., additional, Mailliez, A., additional, Priou, F., additional, Tredan, O., additional, Dalenc, F., additional, Perrin, C., additional, Timar David, M., additional, Dohollou, N., additional, Teixeira, L., additional, Brocard, F., additional, Arnaud, A., additional, Delaloge, S., additional, Spano, J.-P., additional, Mansi, L., additional, Damian, F., additional, Pedrini, J., additional, Aleixo, S., additional, Hegg, R., additional, Junior, R., additional, Schmidt, M., additional, Wenzel, C., additional, Grischke, E.-M., additional, Just, M., additional, Harbeck, N., additional, Schumacher, C., additional, Peters, U., additional, Fischer, D., additional, Forstbauer, H., additional, Liersch, R., additional, Warner, E., additional, Bouganim, N., additional, Doyle, C., additional, Price Hiller, J., additional, Vandenberg, T., additional, Pavic, M., additional, Robinson, A., additional, Roldan Urgoiti, G., additional, Califaretti, N., additional, Alacacioglu, A., additional, Gumus, M., additional, Yalcin, B., additional, Cicin, I., additional, Kose, F., additional, Uygun, K., additional, Kaplan, M., additional, Cubukcu, E., additional, Harries, M., additional, Miles, D., additional, Doval, D., additional, Gupta, S., additional, Mohapatra, P., additional, Chatterjee, S., additional, Ghadyalpatil, N., additional, Singhal, M., additional, Nag, S., additional, Agarwal, A., additional, Wolf, I., additional, Gal Yam, E., additional, Yerushalmi, R., additional, Peretz, T., additional, Fried, G., additional, Ben Baruch, N., additional, Katz, D., additional, Hamilton, E., additional, Kayali, F., additional, Brufsky, A., additional, Telli, M., additional, Wright, G., additional, Oyola, R., additional, Rakowski, T., additional, Graff, S., additional, Tjulandin, S., additional, Aparicio, A., additional, Ruiz Borrego, M., additional, Merino, L., additional, Guerra Martinez, J., additional, Lopez, E., additional, Yamashita, T., additional, Ohtani, S., additional, Inoue, K., additional, Ito, Y., additional, Niikura, N., additional, Nakayama, T., additional, Sagara, Y., additional, Yanagita, Y., additional, Kamada, Y., additional, Kaneko, K., additional, Nervo, A., additional, Eniu, A., additional, Schenker, M., additional, Priester, P., additional, Melichar, B., additional, Zimovjanova, M., additional, Sormova, P., additional, Sufliarsky, J., additional, Kakalejcik, M., additional, Belbaraka, R., additional, Errihani, H., additional, Le Than, D., additional, Pham, D., additional, Aravantinos, G., additional, Papadimitriou, C., additional, Koumakis, G., additional, Papandreou, C., additional, Podolski, P., additional, and Tabane, K., additional

Published
2021
Full Text
View/download PDF

27. Prospektive, multizentrische Registerstudie zur Evaluation der gezielten, axillären Dissektion (TAD) nach Clipmarkierung von klinisch suspekten Lymphknoten beim primären Mammakarzinom (SenTa)

Author

Reinisch, M, additional, Heil, J, additional, Rueland, A, additional, Seiberling, C, additional, Harrach, H, additional, Schindowski, D, additional, Lubitz, J, additional, Hellerhoff, K, additional, Ankel, C, additional, Graßhoff, ST, additional, Deuschle, P, additional, Hanf, V, additional, Belke, K, additional, Dall, P, additional, Dorn, J, additional, Kaltenecker, G, additional, Potenberg, J, additional, Blohmer, JU, additional, Kostara, A, additional, Breit, E, additional, Holtschmidt, J, additional, Traut, E, additional, and Kuemmel, S, additional

Published
2021
Full Text
View/download PDF

30. Safety outcomes from monarchE: phase 3 study of abemaciclib combined with endocrine therapy (ET) for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer (EBC)

Author

Reinisch, M, additional, Rugo, HS, additional, O’Shaughnessy, J, additional, Song, C, additional, Broom, R, additional, Gumus, M, additional, Yamashita, T, additional, San Antonio, B, additional, Shahir, A, additional, Zimmermann, A, additional, and Zagouri, F, additional

Published
2021
Full Text
View/download PDF

31. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib plus adjuvant endocrine therapy for high-risk early breast cancer

Author

Reinisch, M, additional, O’Shaughnessy, J, additional, Rastogi, P, additional, Johnston, S, additional, Martin, M, additional, Harbeck, N, additional, Toi, M, additional, YH, Im, additional, Shao, ZM, additional, Kellokumpu Lehtinen, PL, additional, Huang, CS, additional, Tryakin, A, additional, Goetz, M, additional, Rugo, H, additional, Senkus, E, additional, Testa, L, additional, Andersson, M, additional, Tamura, K, additional, Steger, G, additional, Del Mastro, L, additional, Cox, J, additional, Forrester, T, additional, Sherwood, S, additional, Li, X, additional, and Wei, R, additional

Published
2021
Full Text
View/download PDF

32. Studiennetzwerk Rhein-Ruhr: eine erfolgreiche Kooperation zur Verbesserung der Patientenversorgung

Author

Reinisch, M, additional, Schindowski, D, additional, Nusch, A, additional, van Heumen, K, additional, Rüland, A, additional, von Schumann, R, additional, Balwanz, AE, additional, Breit, E, additional, Pollmanns, A, additional, Rezek, D, additional, Brunotte, D, additional, Strunk, C, additional, Brune, MT, additional, Selbach, J, additional, Wortmann, A, additional, Pursche, T, additional, Traut, E, additional, and Kuemmel, S, additional

Published
2021
Full Text
View/download PDF

33. Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC) : Secondary and exploratory results of phase 3b RIBECCA study

Author

Decker, T., Fasching, P.A., Nusch, A., Hartkopf, A., Heinrich, B.J., Kurbacher, C.M., Fuchs, R., Tesch, H., Krabisch, P., Huober, J., Kümmel, S., Brucker, S.Y., Janni, W., Schneeweiss, A., Schuler, Martin, Fehm, T.N., Lüftner, D., C. Quiering, Kreuzeder, J., and Reinisch, M.

Subjects
Medizin
Published
2021

34. Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA

Author

Marme, F., Hanusch, C., Furlanetto, J., Denkert, C., Link, T., Untch, M., Blohmer, J-U., Jackisch, C., Reinisch, M., Rhiem, K. E., Schneeweiss, A., Solbach, C., Schoellhorn, L., Fasching, P. A., Rey, J., Loibl, S., Marme, F., Hanusch, C., Furlanetto, J., Denkert, C., Link, T., Untch, M., Blohmer, J-U., Jackisch, C., Reinisch, M., Rhiem, K. E., Schneeweiss, A., Solbach, C., Schoellhorn, L., Fasching, P. A., Rey, J., and Loibl, S.

Published
2021

35. Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer

Author

Rugo, H., primary, O’Shaughnessy, J., additional, Song, C., additional, Broom, R., additional, Gumus, M., additional, Yamashita, T., additional, San Antonio, B., additional, Shahir, A., additional, Zimmermann, A., additional, Zagouri, F., additional, and Reinisch, M., additional

Published
2021
Full Text
View/download PDF

39. 172P Gene expression in early breast cancer (EBC) patients (pts) with relapse despite pathologic complete response (pCR): An intra- and interindividual (matched control) analysis

Author

Bruzas, S., primary, Kümmel, S., additional, Harbeck, N., additional, Schmid, P., additional, Cortés, J., additional, Seiberling, C., additional, Chiari, O., additional, Harrach, H., additional, Ataseven, B., additional, Dyson, M., additional, Traut, E., additional, Theuerkauf, I., additional, Gebauer, D., additional, Gluz, O., additional, and Reinisch, M., additional

Published
2020
Full Text
View/download PDF

40. 293P Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases

Author

Bachelot, T., primary, Lin, N.U., additional, Murthy, R.K., additional, Hurvitz, S.A., additional, Borges, V., additional, Oliveira, M., additional, Oakman, C., additional, Khan, S., additional, Lynch, C., additional, Westbrook, K., additional, Doyle, C., additional, Reinisch, M., additional, Colleoni, M.A., additional, Slamon, D., additional, Hortobagyi, G.N., additional, Winer, E.P., additional, McGoldrick, S., additional, An, X., additional, and Loibl, S., additional

Published
2020
Full Text
View/download PDF

41. LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

Author

Miles, D.W., primary, Gligorov, J., additional, André, F., additional, Cameron, D., additional, Schneeweiss, A., additional, Barrios, C.H., additional, Xu, B., additional, Wardley, A.M., additional, Kaen, D., additional, Andrade, L., additional, Semiglazov, V., additional, Reinisch, M., additional, Patre, M., additional, Morales, L., additional, Russell, K., additional, Donica, M., additional, and O'Shaughnessy, J., additional

Published
2020
Full Text
View/download PDF

44. 86P Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial

Author

Reinisch, M., primary, Untch, M., additional, Reimer, T., additional, Mahlberg, R.J.C., additional, Aydogdu, M., additional, Hitschold, T., additional, Jackisch, C., additional, Marmé, F., additional, Lück, H-J., additional, Ladda, E., additional, Schmatloch, S., additional, Schmidt, M., additional, Klare, P., additional, Sinn, B.V., additional, Stickeler, E., additional, Seiler, S., additional, Rey, J., additional, Klutinus, N., additional, Möbus, V., additional, and Loibl, S., additional

Published
2020
Full Text
View/download PDF

45. Prospective, multicenter registry trial to evaluate the clinical feasibility of targeted axillary dissection (TAD) in patients (pts) with breast cancer (BC) and core biopsy proven axillary involvement (cN+)

Author

Reinisch, M., primary, Heil, J., additional, Rüland, A., additional, Seiberling, C., additional, Harrach, H., additional, Schindowski, D., additional, Lubitz, J., additional, Ankel, C., additional, Graßhoff, S.-T., additional, Deuschle, P., additional, Hanf, V., additional, Holtschmidt, J., additional, Traut, E., additional, Kuehn, T., additional, and Kuemmel, S., additional

Published
2019
Full Text
View/download PDF

46. Abstract P1-17-07: Cancer management and outcome of very young non-pregnant patients with breast cancer diagnosed at 40 years or younger– GBG 29

Author

Seiler, S, primary, Schmatloch, S, additional, Reinisch, M, additional, Neunhöffer, T, additional, Schmidt, M, additional, Bechtner, C, additional, Marmé, F, additional, Wagner, M, additional, Möbus, V, additional, Reimer, T, additional, Kleine-Tebbe, A, additional, Sinn, B, additional, Stickeler, E, additional, Untch, M, additional, Janni, W, additional, Seither, F, additional, and Loibl, S, additional

Published
2019
Full Text
View/download PDF

47. 247P Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study

Author

Decker, T., Fasching, P.A., Nusch, A., Hartkopf, A., Heinrich, B.J., Kurbacher, C.M., Fuchs, R., Tesch, H., Krabisch, P., Huober, J., Kümmel, S., Brucker, S.Y., Janni, W., Schneeweiss, A., Schuler, M., Fehm, T.N., Lüftner, D., C. Quiering, Kreuzeder, J., and Reinisch, M.

Published
2021
Full Text
View/download PDF

50. Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients

Author

Reinisch, M., primary, Seiler, S., additional, Hauzenberger, T., additional, Schmatloch, S., additional, Strittmatter, H.-J., additional, Zahm, D.-M., additional, Thode, C., additional, Jackisch, C., additional, Strik, D., additional, Moebus, V., additional, Reimer, T., additional, Sinn, B., additional, Stickeler, E., additional, Marme, F., additional, Janni, W., additional, Kamischke, A., additional, Rudlowski, C., additional, Nekljudova, V., additional, von Minckwitz, G., additional, and Loibl, S., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results